Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn

Martin P. Moya, Andrew J. Gow, Robert M. Califf, Ronald N. Goldberg, Jonathan S. Stamler

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Inhaled nitric oxide is used to alleviate pulmonary hypertension and hypoxaemia, but generates toxic free radicals and oxides of nitrogen (NO x), which can cause rebound-hypoxia and additional pulmonary and other morbidity. To address these problems, we assessed the efficacy of inhaled O-nitrosoethanol gas (ENO) as a novel alternative means of providing nitric oxide bioactivity in the treatment of persistent pulmonary hypertension of newborns. We administered ENO over 4 h to seven neonates who required assisted ventilation, and who had an oxygenation index of 25 or more. ENO was then shut off for 15 min before start of treatment with inhaled nitric oxide. Our results show that ENO produced sustained improvements in postductal arterial oxygenation and systemic haemodynamics, which were maintained during the off-drug observation period. Increases in methaemoglobinaemia were modest and toxic NO x were not detected. Thus, ENO can improve oxygenation and systemic haemodynamics in neonates, and seems to reduce rebound hypoxaemia and production of toxic byproducts.

Original languageEnglish
Pages (from-to)141-143
Number of pages3
JournalThe Lancet
Volume360
Issue number9327
DOIs
Publication statusPublished - 13 Jul 2002
Externally publishedYes

Fingerprint

Persistent Fetal Circulation Syndrome
Poisons
Nitric Oxide
Gases
Hemodynamics
Nitrogen Oxides
Methemoglobinemia
Pulmonary Hypertension
Free Radicals
Ventilation
Observation
Morbidity
Lung
Pharmaceutical Preparations
ethyl nitrite
Hypoxia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Moya, M. P., Gow, A. J., Califf, R. M., Goldberg, R. N., & Stamler, J. S. (2002). Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. The Lancet, 360(9327), 141-143. https://doi.org/10.1016/S0140-6736(02)09385-6

Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. / Moya, Martin P.; Gow, Andrew J.; Califf, Robert M.; Goldberg, Ronald N.; Stamler, Jonathan S.

In: The Lancet, Vol. 360, No. 9327, 13.07.2002, p. 141-143.

Research output: Contribution to journalArticle

Moya, MP, Gow, AJ, Califf, RM, Goldberg, RN & Stamler, JS 2002, 'Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn', The Lancet, vol. 360, no. 9327, pp. 141-143. https://doi.org/10.1016/S0140-6736(02)09385-6
Moya, Martin P. ; Gow, Andrew J. ; Califf, Robert M. ; Goldberg, Ronald N. ; Stamler, Jonathan S. / Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. In: The Lancet. 2002 ; Vol. 360, No. 9327. pp. 141-143.
@article{c9570564cd5c45c98f9bcee95fceca8d,
title = "Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn",
abstract = "Inhaled nitric oxide is used to alleviate pulmonary hypertension and hypoxaemia, but generates toxic free radicals and oxides of nitrogen (NO x), which can cause rebound-hypoxia and additional pulmonary and other morbidity. To address these problems, we assessed the efficacy of inhaled O-nitrosoethanol gas (ENO) as a novel alternative means of providing nitric oxide bioactivity in the treatment of persistent pulmonary hypertension of newborns. We administered ENO over 4 h to seven neonates who required assisted ventilation, and who had an oxygenation index of 25 or more. ENO was then shut off for 15 min before start of treatment with inhaled nitric oxide. Our results show that ENO produced sustained improvements in postductal arterial oxygenation and systemic haemodynamics, which were maintained during the off-drug observation period. Increases in methaemoglobinaemia were modest and toxic NO x were not detected. Thus, ENO can improve oxygenation and systemic haemodynamics in neonates, and seems to reduce rebound hypoxaemia and production of toxic byproducts.",
author = "Moya, {Martin P.} and Gow, {Andrew J.} and Califf, {Robert M.} and Goldberg, {Ronald N.} and Stamler, {Jonathan S.}",
year = "2002",
month = "7",
day = "13",
doi = "10.1016/S0140-6736(02)09385-6",
language = "English",
volume = "360",
pages = "141--143",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9327",

}

TY - JOUR

T1 - Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn

AU - Moya, Martin P.

AU - Gow, Andrew J.

AU - Califf, Robert M.

AU - Goldberg, Ronald N.

AU - Stamler, Jonathan S.

PY - 2002/7/13

Y1 - 2002/7/13

N2 - Inhaled nitric oxide is used to alleviate pulmonary hypertension and hypoxaemia, but generates toxic free radicals and oxides of nitrogen (NO x), which can cause rebound-hypoxia and additional pulmonary and other morbidity. To address these problems, we assessed the efficacy of inhaled O-nitrosoethanol gas (ENO) as a novel alternative means of providing nitric oxide bioactivity in the treatment of persistent pulmonary hypertension of newborns. We administered ENO over 4 h to seven neonates who required assisted ventilation, and who had an oxygenation index of 25 or more. ENO was then shut off for 15 min before start of treatment with inhaled nitric oxide. Our results show that ENO produced sustained improvements in postductal arterial oxygenation and systemic haemodynamics, which were maintained during the off-drug observation period. Increases in methaemoglobinaemia were modest and toxic NO x were not detected. Thus, ENO can improve oxygenation and systemic haemodynamics in neonates, and seems to reduce rebound hypoxaemia and production of toxic byproducts.

AB - Inhaled nitric oxide is used to alleviate pulmonary hypertension and hypoxaemia, but generates toxic free radicals and oxides of nitrogen (NO x), which can cause rebound-hypoxia and additional pulmonary and other morbidity. To address these problems, we assessed the efficacy of inhaled O-nitrosoethanol gas (ENO) as a novel alternative means of providing nitric oxide bioactivity in the treatment of persistent pulmonary hypertension of newborns. We administered ENO over 4 h to seven neonates who required assisted ventilation, and who had an oxygenation index of 25 or more. ENO was then shut off for 15 min before start of treatment with inhaled nitric oxide. Our results show that ENO produced sustained improvements in postductal arterial oxygenation and systemic haemodynamics, which were maintained during the off-drug observation period. Increases in methaemoglobinaemia were modest and toxic NO x were not detected. Thus, ENO can improve oxygenation and systemic haemodynamics in neonates, and seems to reduce rebound hypoxaemia and production of toxic byproducts.

UR - http://www.scopus.com/inward/record.url?scp=0037072098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037072098&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)09385-6

DO - 10.1016/S0140-6736(02)09385-6

M3 - Article

C2 - 12126827

AN - SCOPUS:0037072098

VL - 360

SP - 141

EP - 143

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9327

ER -